Sapient Therapeutics Announces Positive Phase 1 Results in Part B of its Solid Dose Prescription CBD Study

London, UK and Melbourne, Australia, 19 December 2023: Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of Part B of its Phase 1 comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.… Continue reading Sapient Therapeutics Announces Positive Phase 1 Results in Part B of its Solid Dose Prescription CBD Study

Sapient Therapeutics Announces Positive Phase 1 Results in Part A of its Solid Dose Prescription CBD Study

Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of its Phase 1 Part A comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.